HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange
15.6.2026 11:15:00 CEST | Business Wire | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity.
HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/
HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange
Emmanuelle Deba, Chair of the Board of Directors at HUI S.p.A., stated:
"The response from traditional equity markets and our entry into continuous trading supported by a premier European market maker validate our institutional maturity. Concurrently, our expansion into digital assets addresses the strong demand for dynamism and liquidity from our rapidly expanding international community of investors."
Robert Baker, Managing Partner of Nimbus Capital, commented:
“We are pleased to support HUI as it bridges traditional public markets with the next generation of Web3 infrastructure. Nimbus Capital focuses on connecting structured financing, public-market access, and digital asset growth, and HUI represents a strong example of that convergence. As active partners and investors in HUI S.p.A., we look forward to supporting the company’s continued expansion, liquidity strategy, and broader digital asset roadmap.”
Nimbus Capital’s participation further strengthens HUI’s position as a listed platform connecting regulated equity financing with Web3 innovation. Through its global network across public markets, digital assets, exchanges, liquidity providers, and institutional investors, Nimbus Capital is well positioned to support HUI S.p.A.’s next phase of growth by assisting in its CEX listing on a Tier 1 exchange.
HUI v3: 1.2M Lines of code redefining productivity and AI
The highly anticipated v3 Open Beta is set to debut in a matter of days, culminating a massive 3-year engineering project focused on rewriting a proprietary codebase exceeding 1.2 million lines of code optimized for Web3 standards. HUI v3 introduces a revolutionary data model for Artificial Intelligence: unlike generic software (such as Gemini, ChatGPT, or Claude), HUI’s AI leverages 10 years of highly qualified, proprietary contact and behavioural data captured directly from client startups' core processes rather than third-party web crawling.
The architecture also integrates the Enry’s Model (IP inherited from its incubation at Enry’s Island), injecting unique business and process know-how into the platform, allowing startups to deploy vertical AI Agents tailored to best practices shared by accelerators and VCs.
Victor Pizzoni, Board Member in charge of Corporate Affairs, commented:
"With HUI v3, we are bridging a structural gap where technology giants like Meta (which never managed to get its community to adopt Workplace) and Microsoft (which never managed to do the opposite, namely connecting its MS Office suite with LinkedIn after its acquisition) have historically struggled: seamlessly uniting the operational efficiency of HUI.Desk with the ecosystem relational network of HUI.play. Furthermore, our new Finance app centralizes corporate operations, removing spreadsheet fragmentation and automating fundraising and Investor Relations workflows."
HUI v4: Single-founder startups and native crypto approach
The company has also unveiled the framework for its upcoming HUI v4, which has been under development for the past 12 months. This next-generation release will enable highly scalable single-founder startups allowing a single human founder to manage complex operations through multiple AI agents coordinated by HUI and deliver a comprehensive multi-client porting across Web, Mobile, Desktop, Smart Speaker, and Smart TV Apps.
On the digital asset front, the ecosystem capitalizes on years of peer-to-peer transactions powered by the HUI Coin. Meeting overwhelming demand from its user base and institutional shareholders, HUI officially announced the upcoming launch of its corporate Utility Token, which will be listed shortly on a major tier-one global crypto exchange (stay tuned).
Alessandro Pacciana, Investor Relations at HUI S.p.A., concluded:
"Our roadmap (which our amazing decentralized team of tech & business talents across Italy, UK, India, Ukraine, Far East and the US has been working on for years) positions HUI as the definitive operating system for the global VC and startup movement, replicating the paradigm shift that Microsoft Office brought to PCs in the 1990s. The imminent listing of our utility token on a major global exchange, running in parallel with our public equity consolidation in Vienna, serves as a major turning point for our decentralized ecosystem's value realization: stay tuned."
About HUI S.p.A.
HUI S.p.A. is the world's first integrated SuperApp and SaaS platform listed on the Vienna Stock Exchange (Wiener Börse). Emerging from the Enry’s Island ecosystem and powered by the Enry’s Model, HUI aggregates all corporate management, collaboration, finance, networking, and blockchain functions required by the international startup and Venture Capital ecosystem into a unified software environment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260612936893/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom